
CardieX
Vascular biomarker technology for cardiovascular health management.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | N/A | AUD4.1m | Post IPO Equity |
Total Funding | 000k |


AUD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | 25 % | - | 20 % | (17 %) | 20 % | 107 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (75 %) | (60 %) | (60 %) | (83 %) | (240 %) | (250 %) | (58 %) |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (75 %) | (60 %) | (60 %) | (100 %) | (240 %) | (317 %) | (62 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
CardieX is a global health technology company, listed on the Australian Stock Exchange, that designs, manufactures, and markets solutions for cardiovascular health disorders. The company was founded in 1994 and is headquartered in Sydney, Australia. Its core business revolves around its patented and FDA-cleared SphygmoCor® technology, which is considered a market leader for non-invasively measuring central blood pressure and arterial stiffness. This technology provides deeper insights into cardiovascular health than traditional blood pressure measurements by assessing the pressure that the heart, brain, and kidneys directly experience.
The company operates through two main divisions: ATCOR and CONNEQT. The ATCOR division focuses on the clinical market, supplying medical devices to specialist clinicians, pharmaceutical companies for clinical trials, and research institutions. Its technology is used by 8 of the top 10 pharmaceutical companies and in all of the top 20 U.S. hospitals. The CONNEQT division, launched in 2021, targets the consumer and home healthcare market. Its product line includes the CONNEQT Pulse, a dual blood pressure monitor for home use, and the upcoming CONNEQT Band, a health wearable. These devices integrate the SphygmoCor technology into an ecosystem of connected apps and digital solutions for consumers, remote patient monitoring, and decentralized clinical trials.
The company's business model is transitioning towards recurring revenue streams. This includes sales and leasing of devices, technology licensing, and a move towards subscription-based services for both its clinical (XCEL) and consumer (Pulse) platforms, which offer features like on-demand cardiology reports. CardieX is led by Group CEO Craig Cooper, a serial entrepreneur who co-founded Boost Mobile (USA) and has an extensive background in venture capital, digital media, and technology.
Keywords: cardiovascular diagnostics, arterial stiffness, central blood pressure, vascular biomarker technology, SphygmoCor, remote patient monitoring, wearable health devices, hypertension management, digital health solutions, non-invasive diagnostics, ATCOR, CONNEQT Pulse, clinical trials, medical devices, home health monitoring, telehealth, vital signs monitoring, cardiovascular disease, FDA-cleared, biometric monitor
Tech stack
Investments by CardieX
Edit